McKinley Carter Wealth Services Inc. Sells 680 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

McKinley Carter Wealth Services Inc. decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,111 shares of the medical research company’s stock after selling 680 shares during the period. Thermo Fisher Scientific comprises about 1.1% of McKinley Carter Wealth Services Inc.’s investment portfolio, making the stock its 18th biggest position. McKinley Carter Wealth Services Inc.’s holdings in Thermo Fisher Scientific were worth $4,144,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of TMO. Cohen Lawrence B lifted its holdings in shares of Thermo Fisher Scientific by 2.0% in the second quarter. Cohen Lawrence B now owns 10,185 shares of the medical research company’s stock worth $2,991,000 after buying an additional 195 shares in the last quarter. Private Trust Co. NA grew its position in Thermo Fisher Scientific by 66.7% in the 2nd quarter. Private Trust Co. NA now owns 3,273 shares of the medical research company’s stock valued at $961,000 after acquiring an additional 1,310 shares in the last quarter. Parallel Advisors LLC grew its position in Thermo Fisher Scientific by 4.4% in the 1st quarter. Parallel Advisors LLC now owns 9,416 shares of the medical research company’s stock valued at $2,578,000 after acquiring an additional 393 shares in the last quarter. Barrett Asset Management LLC grew its position in Thermo Fisher Scientific by 0.4% in the 1st quarter. Barrett Asset Management LLC now owns 111,500 shares of the medical research company’s stock valued at $30,520,000 after acquiring an additional 395 shares in the last quarter. Finally, Gateway Investment Advisers LLC grew its position in Thermo Fisher Scientific by 45.5% in the 2nd quarter. Gateway Investment Advisers LLC now owns 38,146 shares of the medical research company’s stock valued at $11,203,000 after acquiring an additional 11,928 shares in the last quarter. 88.21% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have weighed in on TMO. Needham & Company LLC lifted their target price on Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Credit Suisse Group reiterated a “buy” rating and issued a $310.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Argus lifted their price objective on Thermo Fisher Scientific from $285.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Barclays set a $330.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Monday, July 15th. Finally, Wolfe Research assumed coverage on Thermo Fisher Scientific in a research note on Thursday, May 30th. They issued an “outperform” rating for the company. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average price target of $303.17.

TMO stock traded up $2.84 during trading on Friday, hitting $276.15. 992,900 shares of the company’s stock were exchanged, compared to its average volume of 1,602,729. The business has a 50-day moving average price of $286.98 and a two-hundred day moving average price of $272.14. The stock has a market capitalization of $109.45 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 1.79 and a beta of 1.11. Thermo Fisher Scientific Inc. has a 52-week low of $208.34 and a 52-week high of $305.45. The company has a current ratio of 1.49, a quick ratio of 1.07 and a debt-to-equity ratio of 0.58.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share for the quarter, topping the consensus estimate of $3.01 by $0.03. The firm had revenue of $6.32 billion during the quarter, compared to analysts’ expectations of $6.31 billion. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The firm’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.75 earnings per share. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 12.24 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Tuesday, September 17th will be paid a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date of this dividend is Monday, September 16th. Thermo Fisher Scientific’s dividend payout ratio is currently 6.83%.

In other Thermo Fisher Scientific news, Director C Martin Harris sold 275 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $270.73, for a total value of $74,450.75. Following the completion of the sale, the director now owns 6,433 shares in the company, valued at $1,741,606.09. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $268.29, for a total value of $670,725.00. Following the completion of the transaction, the chief financial officer now directly owns 40,029 shares in the company, valued at approximately $10,739,380.41. The disclosure for this sale can be found here. In the last quarter, insiders sold 52,775 shares of company stock valued at $14,986,676. 0.45% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Further Reading: What are defining characteristics of a correction?

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.